Skip to content

UroGen Pharma Ltd.

URGN

CIK 0001668243

← back to feed
Revenue (TTM)
$122.91M
+346.9% YoY Q1 May 2026
Net Income (TTM)
−$150.7M
−309.2% YoY Q1 May 2026
EPS Diluted (TTM)
—
Q1 May 2026
Gross Margin
89.2%
Q1 May 2026
Operating Margin
-102.5%
Q1 May 2026
Net Margin
-122.6%
Q1 May 2026
Free Cash Flow (TTM)
−$145M
Q1 May 2026
Cash
$109.97M
Q1 May 2026
Total Debt
$189.53M
Q1 May 2026
Shares Outstanding
48.72M sh
Q1 May 2026

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings